Comparison · NCT00968708-sae
Alogliptin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Alogliptin vs Placebo: serious adverse events. Trial comparisons, record NCT00968708-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00968708-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.336 | 0.318 | 0.354 | wilson | |
| Risk in group 2 | 0.355 | 0.337 | 0.374 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0196 | -0.0449 | 0.00586 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.945 | 0.878 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.917 | 0.82 | 1.03 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Alogliptin than on Placebo | 51.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Alogliptin | Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and \<60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR \<30 mL/min). | 907 | 2,701 | EG001 |
| Group 2 | Placebo | Alogliptin placebo matching tablets, orally, once daily. | 952 | 2,679 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
Source ClinicalTrials.gov
Trial
- Title
- Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
- NCT number
- NCT00968708
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2, Acute Coronary Syndrome
- Interventions
- Alogliptin, Placebo
- Lead sponsor
- Takeda
- Results first posted
- 2014-04-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00968708?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00968708-sae